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Abstract
Members of the Nod-like receptor (NLR) family recognize intracellular pathogens and recruit a variety of effector molecules,
including pro-caspases and kinases, which in turn are implicated in cytokine processing and NF-kB activation. In order to
elucidate the intricate network of NLR signaling, which is still fragmentary in molecular terms, we applied comprehensive
yeast two-hybrid analysis for unbiased evaluation of physical interactions between NLRs and their adaptors (ASC, CARD8) as
well as kinase RIPK2 and inflammatory caspases (C1, C2, C4, C5) under identical conditions. Our results confirmed the
interaction of NOD1 and NOD2 with RIPK2, and between NLRP3 and ASC, but most importantly, our studies revealed
hitherto unrecognized interactions of NOD2 with members of the NLRP subfamily. We found that NOD2 specifically and
directly interacts with NLRP1, NLRP3 and NLRP12. Furthermore, we observed homodimerization of the RIPK2 CARD domains
and identified residues in NOD2 critical for interaction with RIPK2. In conclusion, our work provides further evidence for the
complex network of protein-protein interactions underlying NLR function.
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Introduction
Nearly a decade ago, the NLR (nucleotide-binding domain and
leucine rich repeat containing) family (recently reviewed in [1–3])
of intracellular microbial sensors was introduced with the
discovery of NOD1 and its role in NF-kB activation [4]. NLR
proteins are proposed to survey the cytoplasm for the presence of
microbial invaders and endogenous danger signals [5,6]. Today, it
is widely accepted that NLR proteins are critical to the regulation
of the innate immune response and, hence, were progressively
appreciated for their critical role in host defense to pathogens.
A total of 22 NLR family members have been identified in
humans so far (for members and nomenclature see [7] and http://
www.genenames.org/genefamily/nacht.html). Individual NLRs
specifically recognize microbial derived non-self products such as
peptidoglycan-derived molecules [8,9], viral dsRNA, bacterial
toxins, as well as host-derived danger-molecules like uric acid
crystals [10–12]. Structurally, NLRs are large multi-domain
proteins, that contain N-terminal effector domains for binding
downstream signaling molecules, a nucleotide-binding oligomer-
ization domain (NACHT), a winged helix (WH), a superhelical
(SH) and a C-terminal leucine rich repeat (LRR) receptor domain
[13]. NLR proteins are assigned to particular subgroups according
to their respective effector domain (PYD, CARD, BIR, and
unclassified).
NLRs prevail in the cytoplasm in a dormant form and
are activated through direct or indirect binding of ligands to the
LRR-receptor domain. Concomitant conformational changes
unlock the NACHT domain leading to oligomerization and the
formation of a signaling platform, which is capable of eliciting
specific immune responses by the recruitment of specific adaptor
molecules as well as effector molecules like inflammatory pro-
caspases and kinases [14].
The current model of NLR signaling proposes that the CARD-
containing NOD proteins NOD1 and NOD2 interact with the
CARD-containing kinase RIPK2 (RIP2/RICK) which further
leads to the activation of the NF-kB pathway and MAPK
pathways [3]. In contrast, the PYD-containing NLRP proteins
(formerly named Nalps) drive caspase-activation by binding to the
adaptor protein ASC leading to the processing of pro-inflamma-
tory cytokines [15,16].
Despite their undisputed importance in host defense, definite
biological roles for most NLRs await to be assigned. Comprehensive
molecular interaction maps are fragmentary and assessment of NLR
signaling networks as a whole, hitherto, is hardly in its early stages.
Therefore, the functional and mechanistically details of NLR
activation as well as the molecular details of the subsequent initiation
of signaling cascades remain elusive. Crucial questions, for instance
how these receptors distinguish between self, pathogens, commensal
bacteria, and endogenous danger signals, are still open.
To substantiate our understanding of NLR function, this study
aimed to decipher the molecular mechanisms of NLR signaling by
assessing their protein interaction network in an unbiased,
systematic approach. Employing comprehensive yeast two-hybrid
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effector domains. Described connections were critically evaluated
under identical conditions and we were able to identify novel
interactions of NOD2 with distinct members of the NLRP
subfamily, namely NLRP1, -3 and -12. Furthermore, we observed
homodimerization of the RIPK2 CARD domains and, based on
molecular modeling and mutational analysis, identified positions in
the CARD1 domain of NOD2 that are essential to mediate
interaction with RIPK2.
Results and Discussion
NLR effector domain interactions – yeast two-hybrid
analysis
To further our understanding of protein interactions engaged in
NLR signaling events, we subjected effector domains of 11 distinct
NLR proteins (NOD1, NOD2, NLRC4, NLRC5, NLRP1,
NLRP2, NLRP3, NLRP7, NLRP10, NLRP11, NLRP12), various
downstream signaling partners or effectors (RIPK2, CARD8,
ASC, PYDC1), as well as CARD domains of assorted caspases
(CASP1, CASP2, CASP4, CASP5, CASP9) to systematic yeast
two-hybrid analysis (see Methods). Bait und prey design was based
on our previous bioinformatical analyses describing comprehen-
sive sequence and structural homology models of NLR CARD and
PYD domains [13].
Preliminary trails revealed feasibility and selectivity of our setup
in monitoring NLR effector domain interaction (data not shown).
Consequently, we conducted yeast transformations in an ‘‘each
against all’’ approach, consisting of an overall number of 676
independent transformations. Thereby, we recorded a total
number of 25 interactions (shown in Figure 1), actually
corresponding to 12 unique pairs of interacting effector domains
(indicated in Table 1). These unique interactions were composed
of previously assigned as well as novel associations. Table 1 shows
the most important NLR-related protein-protein interactions
retrieved from recent scientific literature or selected protein-
protein interaction databases (column 1) and indicates whether the
respective interactions were observed or not observed in the course
of our yeast two-hybrid analysis (column 2). In the following, we
will critically contrast our results with recently published data on
NLR protein-protein interactions.
NOD1. Since its first characterization, the binding of NOD1
and RIPK2 was considered a paradigm interaction of NLR
signaling and subsequently constituted the foundation of the
‘‘induced proximity’’ model of NF-kB activation by NOD1/
RIPK2 [4,17]. The initial study also described co-
immunoprecipitation of NOD1 not only with RIPK2 but also
with several pro-caspases, including pro-caspase-1, -2, -4, and -9
[4]. Subsequently, these findings were supported by another report
of NOD1-mediated enhancement of IL-1b secretion by direct
interaction with pro-caspase-1 [18]. Even though we were able to
detect the CARD-CARD-mediated interaction of NOD1 to
RIPK2, our two-hybrid data provided no evidence of any direct
association of NOD1 CARD with the CARDs of caspase-1, -2, -4,
Figure 1. The interaction matrix. In an ‘‘each against all’’ approach an overall number of 676 (26626) effector domain combinations were
analyzed. A ‘‘+’’ indicates an interaction between a particular pair, whereas ‘‘2’’ symbolizes no interaction. In total, the approach yielded 25 distinct
associations, which actually corresponded to 7 unique pairs of interacting proteins, as well as 5 homodimerizations.
doi:10.1371/journal.pone.0004931.g001
NLR Interactions
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Interaction Result Baits Preys Ref.
NOD1 - NLRC4 not observed NOD1 CARD (1–110), NOD1 CARD (16–108) NLRC4 CARD [28]
NOD1 - NLRP1 not observed NOD1 CARD (1–110), NOD1 CARD (16–108) NLRP1 PYD, NLRP1 CARD [59]
NOD1 - RIPK2 observed NOD1 CARD (1–110), NOD1 CARD (16–108) RIPK2 CARD [4,60]
NOD1 - CASP1 not observed NOD1 CARD (1–110), NOD1 CARD (16–108) CASP1 CARD [4,18]
NOD1 - CASP2 not observed NOD1 CARD (1–110), NOD1 CARD (16–108) CASP2 CARD [4]
NOD1 - CASP4 not observed NOD1 CARD (1–110), NOD1 CARD (16–108) CASP4 CARD [4]
NOD1 - CASP9 not observed NOD1 CARD (1–110), NOD1 CARD (16–108) CASP9 CARD [4]
NOD2 - NLRC4 not observed NOD2 CARD (1), NOD2 CARD (2), NOD2 CARD (1+2) NLRC4 CARD [28,31]
NOD2 - NLRP1 observed
1 NOD2 CARD (1), NOD2 CARD (2), NOD2 CARD (1+2) NLRP1 PYD, NLRP1 PYD+linker [29]
NOD2 - NLRP3 observed NOD2 CARD (1), NOD2 CARD (2), NOD2 CARD (1+2) NLRP3 PYD, NLRP3 PYD+linker [27]*
NOD2 - RIPK2 observed NOD2 CARD (1), NOD2 CARD (2), NOD2 CARD (1+2) RIPK2 CARD [22]
NOD2 - CASP1 not observed NOD2 CARD (1), NOD2 CARD (2), NOD2 CARD (1+2) CASP2 CARD [28,29]
NLRC4 - NLRP1 not observed NLRC4 CARD NLRP1 PYD, NLRP1 CARD [28]
NLRC4 - NLRP3 not observed NLRC4 CARD NLRP3 PYD+linker [28]
NLRC4 - NLRP4 not observed NLRC4 CARD NLRP4 PYD [28]
NLRC4 - ASC observed NLRC4 CARD ASC CARD, ASC PYD [30,61]
NLRC4 - CASP1 not observed NLRC4 CARD CASP1 CARD [28,31,32]
NLRP1 - APAF1 not observed NLRP1 CARD, NLRP1 PYD APAF1 CARD [59]
NLRP1 - ASC not observed NLRP1 CARD, NLRP1 PYD ASC CARD, ASC PYD, ASC full length [42]
NLRP1 - CASP1 not observed NLRP1 CARD, NLRP1 PYD CASP1 CARD [33]
NLRP1 - CASP2 not observed NLRP1 CARD, NLRP1 PYD CASP2 CARD [45]
NLRP1 - CASP5 not observed NLRP1 CARD, NLRP1 PYD CASP5 CARD [33]
NLRP1 - CASP9 not observed NLRP1 CARD, NLRP1 PYD CASP9 CARD [45]
NLRP2 - CARD8 not observed NLRP2 PYD CARD8 CARD [40]
NLRP3 - CARD8 not observed NLRP3 PYD+linker CARD8 CARD [40]
NLRP3 - ASC observed
1 NLRP3 PYD+linker, NLRP3 PYD ASC CARD, ASC PYD, ASC full length [43]
NLRP12 - ASC not observed NLRP12 PYD ASC CARD, ASC PYD, ASC full length [44]
APAF1 - CASP4 not observed APAF1 CARD CASP4 CARD [62]
APAF1 - CASP9 observed APAF1 CARD CASP9 CARD [63,64]
RIPK2 - CASP1 not observed RIPK2 CARD CASP1 CARD [41]
CARD8 - CASP1 observed CARD8 CARD CASP1 CARD [38]
CARD8 - CASP9 not observed CARD8 CARD CASP9 CARD [37]
ASC - CASP1 observed ASC CARD, ASC PYD CASP1 CARD [33,34]
ASC - PYDC1 not observed ASC CARD, ASC PYD PYDC1 PYD [35,36]
Homodimer/-oligomers
NOD1 - NOD1 not observed NOD1 CARD (1–110), NOD1 CARD (8–108) NOD1 CARD (1–110), NOD1 CARD (8–108) [4,21]
NOD2 - NOD2 observed NOD2 CARD (1+2) NOD2 CARD (1+2) [22,23]
NLRP1 - NLRP1 not observed NLRP1 CARD, NLRP1 PYD NLRP1 CARD, NLRP1 PYD [45]
RIPK2 - RIPK2 observed RIPK2 CARD RIPK2 CARD [17]
CARD8 - CARD8 observed CARD8 CARD CARD8 CARD [37,39]
ASC - ASC observed ASC CARD-CARD, ASC PYD-PYD ASC CARD-CARD, ASC PYD-PYD [24,25]
CASP1 - CASP1 not observed CASP1 CARD CASP1 CARD [18]
CASP2 - CASP2 observed CASP2 CARD CASP2 CARD [26]
Respective protein-protein interactions were mined from the scientific literature or retrieved from MiMI [65]. Results represent data from our yeast two-hybrid analysis
(interaction observed or not observed). Baits and preys indicate individual domains tested in our analysis with interacting constructs in bold. References to reported
interactions are specified.
1Initially not observed by ‘‘each against all’’ approach, but observed subsequently with refined constructs.
*No data on a direct interaction.
doi:10.1371/journal.pone.0004931.t001
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constructs were functional, as assessed by interaction with ASC
and Apaf-1, respectively (discussed below).
Recently, NMR as well as crystallographic data on the three-
dimensional structure of the NOD1 CARD were presented [19–
21]. One study suggests CARD homodimerization in a pH-
dependent manner [21]. Interestingly, we did not detect any
CARD-CARD mediated NOD1 homodimer formation in
yeast. However, we observed homodimerization of bacterially
overexpressed and purified NOD1 CARDs in solution (data not
shown). These discrepancies of in vivo and in vitro data presumably
reflect the requirement of considerably elevated local NOD1
CARD concentrations and challenge the relevance of CARD-
mediated homodimer formation in vivo, in particular as endoge-
nous NOD1 levels are thought to be very low.
On the other hand, we obtained two-hybrid data for other
effector domains reinforcing the significance of CARD-CARD-
mediated homodimerization of NLR family members. In accor-
dance with recent reports, we observed NOD2 dimerization in a
CARD-dependent manner [22,23]. Furthermore, we detected an
assortment of other CARD-CARD homodimers of non-NLR
proteins, including the previously described homodimerizations of
ASC [24,25], and caspase-2 [26], as well as the hitherto neglected
intrinsic tendency of RIPK2 CARDs to form homodimers, which
is also reflected by its tendency to form aggregates in living human
cells (data not shown). These interactions were highly specific for
the indicated proteins since homodimers were not detected for any
other CARD-containing proteins.
NOD2. In addition to the NOD1/RIPK2 interaction we were
able to observe the interaction of NOD2 and RIPK2 [22].
Interestingly, on their own neither CARD1, nor CARD2 of
NOD2 was sufficient for the interaction. A RIPK2 interaction
could only be observed with a construct comprising both N-
terminal CARD domains of NOD2. These data agree with the
primary literature and are supported by a recent study describing a
naturally occurring short variant of NOD2 (NOD2-S) featuring
the first and part of the second CARD of the full length protein,
which maintains the interaction to RIP2K [23].
Furthermore, we revealed a hitherto unknown NOD2 interac-
tion with NLRP3. Similar to the interaction of NOD2/RIPK2, we
observed NLRP3 binding to be dependent on both NOD2 CARD
domains. This finding is supported by a recent study, which
postulates a functional link between NOD2 and the NLRP3
inflammasome based on the requirement of both NOD2 and
NLRP3 for MDP mediated IL-1b release [27]. This interaction
was speculated to be dependent on a direct CARD-independent
interaction of these proteins.
Although a direct interaction of NOD2 and caspase-1 was
previously reported [28,29] we did not observe a direct interaction
of NOD2 as well as NOD1 with caspases-1, -2, -4, -5, and -9 in
our system. Taken together this suggests that the NLRC proteins
impact on IL-1b activation rather by influencing the NLRP
inflammasomes than by direct interaction with caspase-1.
NLRC4 (IPAF). In line with the literature, we found a
CARD-CARD-mediated interaction of NLRC4 and ASC [30].
However, we did not observe a direct interaction with caspase-1
[30–32]. Furthermore, we found no evidence of an interaction
with other NLR proteins, including NOD1, NOD2, NLRP1,
NLRP3, and NLRP4 [28,31]. While the interaction of NLRC4
and caspase-1 reportedly is CARD-CARD-mediated, NLRC4 is
supposed to associate with other NLR family members through
heterotypic NACHT-domain interactions [28].
Adaptor proteins. We found oligomerization of ASC
(CARD5, PYCARD) to be mediated by both the CARD as well
as the pyrin domain. The underlying pattern of interactions during
ASC oligomerization was described in detail previously [25]. Our
two-hybrid data foster the importance of both CARD and PYD
during the ASC oligomerization process. We were, however, not
able to detect a postulated CARD-PYD heterotypic association,
indicating that ASC oligomer formation predominantly proceeds
via homotypic CARD-CARD as well as PYD-PYD interactions.
In addition, we confirmed a CARD-CARD-based interaction of
ASC and caspase-1, which was described previously [33,34].
Conversely, no interaction of ASC and its prospective inhibitor
PYDC1 (POP1) was observed [35,36].
For CARD8 (CARDINAL, TUCAN), another prospective
component of the inflammasome, we confirmed formation of
homodimers and interaction with caspase-1 [37–39], whereas
neither binding to NLRP2 nor NLRP3 was observed [40].
Finally, no direct interactions of RIPK2 with the CARD of
caspase-1 [41] could be detected.
NLPRs (NALPs). To date, downstream signal transducers for
the majority of NLRP proteins remain largely unknown. As one of
only a few examples ASC was demonstrated to mediate
downstream NLRP signaling via direct interaction with NLRP1
[42], NLRP3 [43], and NLRP12 [44] in biochemical assays.
Furthermore, a direct binding of NLRP1 to caspase-1 and
caspase-5 [33], as well as caspase-2 and caspase-9 [45] was
proposed.
Remarkably, we could not detect a homotypic PYD-PYD
interaction between the NLRP proteins (NLRP1, NLRP2,
NLRP3, NLRP7, NLRP10, NLRP11, and NLRP12) and the
adaptor protein ASC in our initial ‘‘each against all’’ approach.
The experiment was carried out with ASC-PYD (residues 1–94).
Since interaction of ASC and NLRP3 is supported by distinct
evidence, including genetic interaction data (reviewed in [15]) we
refined our constructs. Indeed we observed interaction of ASC full
length (residues 1–195) with NLRP3 PYD (residues 1–101).
Nonetheless, a direct binding of ASC to other NLRP proteins,
including NLRP1 and NLRP12, was still not observed.
Consequently, these findings led us to postulate the presence of
a new adaptor or effector protein that serves in connecting NLRP
family members to downstream signaling pathways.
Strength of interactions. Currently the strength of NLR
effector-domain interactions was not evaluated in detail. To this
end, we titrated the strength of the detected interactions with 3-
aminotriazol (3-AT). This revealed considerable variation in the
binding affinities of particular pairs of interacting proteins
(Figure 2). The APAF-1 caspase-9 interaction scored strongest in
terms of HIS3 reporter gene activation, followed by RIPK2
CARD homodimer formation. The CARD-CARD-dependent
interaction of NOD1 and RIPK2 as well as the homodimerization
of the ASC CARD domains were comparable in strength,
although lower then the ones reported before. In relation, the
formation of ASC PYD-PYD homodimers as well the CARD-
mediated homodimerizations of caspase-2, CARD8, and NOD2
appeared substantially weak. Interestingly, NOD2 displayed a
significantly lower affinity for RIPK2 compared to NOD1.
Furthermore, NOD2 binding to NLRP3 apparently is of
transient nature as indicated by only slight activation of the
reporter genes.
Interactions in detail
RIPK2 homodimerization/-oligomerization. Figure 3
illustrates the homotypic interaction of RIPK2 CARDs. Two-
hybrid data (left panel) were confirmed in vitro by GST pull down
analysis (right panel). The interaction proved to be specific since
no binding to unrelated proteins was observed.
NLR Interactions
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depends on RIPK2. Upon activation, NOD1 and NOD2 recruit
RIPK2 via homotypic CARD-CARD interactions [17,22]. The
model of ‘‘induced proximity’’ postulates that enforced oligomer
formation of RIPK2 subsequently leads to NOD-dependent
activation of NF-kB. Our data add an additional layer of
complexity in so far as they reveal a NOD-independent RIPK2
CARD dimer/-oligomer formation. Interestingly, in vitro RIPK2
CARD displays strong disposition towards formation of oligomers
when subjected to size exclusion chromatography and forms
aggregates when expressed in human cells (data not shown). Since
we analyzed the mere CARD of RIPK2, further experiments will
be needed to determine whether full length RIPK2 actually forms
dimers or oligomers in vivo and how this relates to control
activation of NF-kB downstream of NOD1/2. However, the
strong tendency of ASC towards formation of aggregates in the
course of apoptosis as well as ASC oligomerization during
apoptosis and inflammation are well characterized [24,38,46,47].
Recently, it was shown that caspase-1 is activated during a
particular form of apoptosis induced by bacteria, termed
pyroptosis, by a large supramolecular complex termed the
pyroptosome that is mostly composed of dimers of ASC [47]. It
is exciting, that ASC and RIPK2, the essential and best studied
downstream adaptor molecules of NLR signaling, display a strong
disposition concerning the formation of homodimers/-oligomers.
Whether RIPK2 aggregation is of functional importance in vivo
remains to be determined.
NOD2/RIPK2 interaction - analysis of critical
residues. Mutations in NOD2 are associated with
susceptibility to granulomatous disorders like Blau syndrome and
Crohn’s disease [48–51]. Recently, systematic mutational analysis
revealed various residues within the CARDs of NOD2 to be
critical for RIPK2-mediated NF-kB activation [52]. It was shown
that mutation of single residues can disrupt the interaction of
NOD2 and RIPK2 and to abrogate NF-kB activation in response
to MDP.
Our previous bioinformatic analysis of NLR effector domains
revealed a high conservation of residues in the acidic patch of the
first NOD2 CARD [13]. Accordingly, we generated two different
single amino acid substitutions (E69K, D70K), as well as a triple
mutation (combining E69K, D70K and E71K) within this acidic
surface. These mutants were monitored for RIPK2 binding. We
observed that the introduction of single amino acid substitutions
within the acidic patch of the CARD1 domain is sufficient to
abolish binding to RIPK2 (Figure 4, left panel). Neither the E69K
nor the D70K substitution of the CARD1-domain interacted with
RIPK2. Consistently, also a triple mutation failed to associate with
RIPK2, whereas an unrelated mutation (R132Q) outside the
anticipated interaction interface did not detectably affect binding
affinity. Impaired RIPK2 binding of mutant proteins was not
merely due to protein instability as demonstrated by similar
expression levels (Figure 4, right panel).
Recently, the structure of the NOD1 CARD domain was solved
both by NMR and X-ray diffraction [19–21]. Based on the
published structure Manon et al. identified residues involved in the
CARD-CARD interaction of RIPK2 and NOD1 [20]. They were
able to demonstrate that the interaction is critically dependent on
three acidic residues in NOD1 CARD and three basic residues in
RIPK2 CARD. These residues of NOD1 correspond to the
residues in NOD2 we found to be crucial for RIPK2 interaction.
Thus, it is likely that both CARD-CARD interactions have a
strong electrostatic component, similar to the characterized
CARD-CARD interaction of APAF1 and caspase-9.
In conclusion, our data confirm the predicted interaction
interface and reveal the mode of NOD2/RIPK2 interaction to be
similar to the binding of APAF1 and caspase-9.
Figure 2. Strength of selected interactions in terms of HIS3
reporter gene activation. The maximum concentration of 3-
aminotrizol supporting visible growth of transformants is indicated.
doi:10.1371/journal.pone.0004931.g002
Figure 3. RIPK2 CARD forms homodimers/-oligomers. Left panel, Yeast two-hybrid analysis revealed that RIPK2 CARD (residues 427–527) forms
homodimers/-oligomers (column 1 on SD/-4). Lamin c (Lam c) was used as control (column 5). Right panel, GST pull down assay. Specific binding of
35S-labeled RIPK2 CARD (residues 427–527) was observed to recombinant expressed GST-RIPK2 CARD (residues 427–527), whereas binding to GST-
Lam c was not detected. SD/-2: SD/-Leu/-Trp, SD/-4: SD/-Ade/-His/-Leu/-Trp.
doi:10.1371/journal.pone.0004931.g003
NLR Interactions
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NLRP12. During initial screening for NLR effector domain
interactions, we obtained data in support of a direct NOD2/
NLRP3 interaction (Figure 1). We found both CARD domains of
NOD2 to be essential for this interaction (data not shown). On their
own, neither the CARD1, nor the CARD2 domain of NOD2 could
mediate significant binding to NLRP3. Initial screening showed that
a longer fragment of NLRP3 (residues 1–189) spanning the PYD-
domain and a linker-region region proximal to the NACHT domain
of NLRP3 did interact with the NOD2 CARD domains. However,
we observed that the PYD domain (residues 1–101) of NLRP3 was
not sufficient to mediate this interaction. This suggested that the
linker region (residues 101–189) between the PYD domain and
NACHT domain of NLRP3 comprises the binding surface for
NOD2.Indeedwe wereableto showinsubsequentexperimentsthat
this particular region of NLRPs is necessary and sufficient for
interaction with NOD2 (see below).
Consequently, we re-assessed NLRP constructs (NLRP1, 2, 7,
10, 11, 12) containing this linker region for putative interactions
with NOD2 (see Methods, Table 2).
Indeed, we now obtained direct interaction of NOD2 and
NLRP1 in a CARD-dependent manner (Figure 5A). Additionally,
we found an interaction between NOD2 and NLRP12. Taken
together, NOD2 CARD1+2 did interact with at least three
different NLRP proteins, namely NLRP1, NLRP3, and NLRP12
however did not associate with NLRP2, NLRP7, NLRP10 and
NLRP11.
In order to substantiate our two-hybrid data, we performed in
vivo co-immunoprecipitation experiments (Figure 5B). These
experiments showed a specific physical interaction of NOD2 and
NLRP3 also in human HEK293T cells.
Interestingly, our data revealed remarkable similarities of
NOD2 binding to RIPK2 and NLRP members. In particular,
neither the first, nor the second CARD of NOD2 was sufficient for
the interaction. Importantly, certain mutations (D70K, triple
mutation) within the acidic patch of NOD2 abolished the
interaction. The E69K mutation, however, abrogated NOD2
association with RIPK2, but not NLRP1, 3, or 12. Consistently,
an unrelated mutation remote to the acidic patch (R132Q) had no
effect. These results are consistent with our finding that the
NOD2/RIPK2 interaction is CARD-CARD-mediated, while the
NOD2/NLRP association employs an as yet to be defined
interaction motif located within the NLRP linker region. However,
it is likely that the NOD2/NLRP interaction also has a strong
electrostatic component, similar to characterized CARD-CARD
interactions. Hence, we propose the occurrence of a basic patch
within the NLRP linker region. It will be interesting to determine,
whether this basic patch is shared by all NLRP members that show
an interaction with NOD2.
NOD2-S interacts with a linker region of NLRP1. An
alternatively spliced, short isoform of NOD2 was recently
identified in human cells [23]. NOD2-S comprises the first 180
residues of NOD2 and was shown to interfere with NOD2-
induced NF-kB activation and IL-1b release in overexpression
assays. It was suggested that this effect is mediated by a direct
interaction with both, NOD2 and RIPK2. In this vein, NOD2-S is
supposed to inhibit NOD2 oligomerization.
Given the similarities of the NOD2/RIPK2 and the NOD2/
NLRP interaction described above, and in light of the affect of
NOD2-S on IL-1b release, which may be functionally mediated by
NLRPs [27,29], we monitored distinct NLRP constructs for
interaction with NOD2-S (residues 1–180).
In line with the results obtained with the NOD2 CARD
domains, NOD2-S interacted with NLRP1, NLRP3, and
NLRP12, but not with other NLRP members (Figure 6).
Since, neither the first nor the second CARD domain of NOD2
was sufficient for the interaction, we hypothesized that a region
connecting CARD1 and CARD2 might play an essential role in
NLRP binding.
To address whether actually this region between the two
CARDs of NOD2 is sufficient for NLRP interaction, we analyzed
three additional constructs (see Table 2). Surprisingly, none of
these NOD2 constructs proved to be capable of interaction with
NLRP1 (Figure 6). Therefore, NOD2-S seems to represent the
shortest version of NOD2 with NLRP1 binding capacity, since
further C-terminal truncations, apparently abrogate the binding,
as exemplified by the absence of a detectable NLRP1 interaction
for NOD2 1–163 and NOD2 1–135. Moreover, a NOD2
construct encompassing a region immediately succeeding the
CARD1 (residues 117–267) failed to interact with NLRP1. In
conjunction with our observation that a single point mutation
(D70K) in NOD2 CARD1 is capable of interfering with NLRP
binding, we therefore propose that in addition to the acidic patch
located in CARD1, the proper overall folding of CARD1 and at
least part of the CARD2 are prerequisite for interaction of NOD2
with NRLP proteins as well as RIPK2.
Figure 4. Interaction of distinct NOD2 mutants with RIPK2. Left panel, Yeast two-hybrid analysis. NOD2 CARD1+2 interacts with RIPK2 CARD
(column 1). No interactions were observed for NOD2 variants harboring a disrupted acidic patch (transformation 2, 3, and 4). An unrelated mutation
not affecting the interaction interface had no effect (column 5). Right panel, Autoradiography of an in vitro transcription/translation of NOD2 proteins.
NOD2 constructs were expressed using similar amounts of DNA and lysates.
doi:10.1371/journal.pone.0004931.g004
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without the adjacent linker region failed to interact with NOD2-S
(Figure 6). Excitingly, our data suggests the PYD to be entirely
dispensable for the NOD2 interaction. For NLRP1, indeed we can
show that a linker region (residues 92–341) is sufficient for NOD2
interaction (Figure 6). Finally, NLRP1, -3, and -12 specifically
interact with NOD2, since no binding to NOD1 (residues 1–110)
was observed (Figure 6).
Taken together, our results considerably narrow the prospective
range of residues necessary for a stable NOD2/NLRP1 interaction
by demonstrating that the constructs NOD2-S (1–180) and
NLRP1 linker (92–341) are still capable of an interaction, while
further truncated versions of NOD2 are not.
Concluding remarks
Regardless of the enormous interest in NLR function during
innate immune response, detailed interaction maps are still not at
hand. To our knowledge, no systematic analysis of NLR protein-
protein interactions was conducted so far. Here, we present a
comprehensive analysis of NLR effector domain interactions. Our
analysis confirmed several well known interactions, like the ones of
NOD1/NOD2 and RIPK2, providing a good proof of principle
for the method used, however, we observed surprisingly few
interactions with adaptor molecules, especially ASC. Even though
we found an interaction of ASC and caspase-1, as well as
homotypic dimerization of the ASC CARD and PYD domain, we
did not observe any interactions with NLRP proteins. Instead, we
demonstrated a novel NOD2/NLRP connection. Thus, our data
on the one hand further substantiate the complexity of NLR
signaling, but on the other hand suggests significant gaps in our
understanding of NLR signaling pathways.
Even though the NLRP subfamily comprises 14 distinct
members, at present information on direct interaction partners is
only available for NLRP1, NLRP3 and NLRP12. The role of ASC
in formation of the NLRP3 inflammasome is well established [40],
however, its involvement in downstream signaling of other NLRP
members is less clear. Interestingly, in vitro data rule out a strict role
for ASC in activation of the NLRP1 inflammasome [53].
Therefore, we propose the existence of as yet unknown
downstream interaction partners for NLRP proteins. Since,
NLRPs are supposed to signal via their N-terminal effector
domains and concomitant homophilic protein-protein interac-
tions, possible contenders for hitherto unknown interactions are
likely to be found within the death domain (DD) superfamily
(recently reviewed in [54]. The DD superfamily comprises four
subfamilies, including the subfamilies of CARD and PYD-
containing proteins. The human genome reveals more than 80
DD superfamily members, implicated primarily in the assembly of
apoptotic and inflammatory complexes. Interestingly, some viruses
have acquired DD-containing sequences that interfere with host
apoptotic and inflammatory responses [55]. It is tempting to
speculate that future research will not only uncover human DD
proteins but also DD homologues in pathogens as NLRP
interaction partners.
However, it was revealed by a recent report that putative NLRP
interacting proteins not necessarily have to belong to the DD
superfamily. It was found that Fas-associated factor 1 (FAF1), a
negative regulator of an NF-kB signaling, directly interacts with
the PYD domains of NLRP2, NRLP3, NRLP7, NRLP10, and
NLRP12 [56].
Yet another possible explanation for the few observed NLRP
downstream interaction partners, may be provided by recently
observed heterotypic interactions among NACHT-domains of
NLRC4 and other NLR proteins (NOD1, NOD2, NLRP1) [28].
Table 2. Cloning of constructs.
Construct name Accession Residue range
Initial ‘‘screening’’
NOD1 CARD (1–110) AF126484 1–110
NOD1 CARD (16–108) AF126484 16–108
NOD2 CARD (1) AF178930 1–116
NOD2 CARD (2) AF178930 135–255
NOD2 CARD (1+2) AF178930 1–267
NLRC4 CARD AF376061 1–96
NLRC5 CARD AF389420 1–98
NLRP1 CARD AB023143 1373–1465
NLRP1 PYD AB023143 1–91
NLRP2 PYD AK000517 1–95
NLRP3 PYD+linker AF054176 1–189
NLRP7 PYD AF464765 1–93
NLRP10 PYD AY154465 1–96
NLRP11 PYD AY095145 1–94
NLRP12 PYD AY095146 1–98
APAF1 CARD AF013263 1–92
RIPK2 CARD AF027706 427–527
CARD8 CARD AF322184 342–430
ASC CARD AB023416 105–195
ASC PYD AB023416 1–94
PYDC1 PYD AF454669 1–95
CASP1 CARD X65019 1–91
CASP2 CARD BC002427 32–121
CASP4 CARD Z48810 1–89
CASP5 CARD U28015 1–128
CASP9 CARD U60521 1–97
Interactions in detail
NOD2 CARD (1+2) E69K AF178930 1–267
NOD2 CARD (1+2) D70K AF178930 1–267
NOD2 CARD (1+2) 3xmut* AF178930 1–267
NOD2 CARD (1+2) R132Q AF178930 1–267
NOD2-S AF178930 1–180
NOD2 1–163 AF178930 1–163
NOD2 1–135 AF178930 1–135
NOD2 117–267 AF178930 117–267
NLRP1, PYD+linker AF298548 1–341
NLRP1 linker AF298548 92–341
NLRP2, PYD+linker AK000517 1–220
NLRP3, PYD AF054176 1–101
NLRP7, PYD+linker AF464765 1–185
NLRP10, PYD+linker AY154465 1–180
NLRP11, PYD+linker AY095145 1–160
NLRP12, PYD+linker AY095146 1–224
ASC full length AB023416 1–195
GenBank [66] accession numbers, featured domains as well as corresponding
amino acid residues are indicated, respectively.
*NOD2 tripled mutation – E69K, D70K, D71K; CARD: caspase activation and
recruitment domain, PYD: pyrin domain.
doi:10.1371/journal.pone.0004931.t002
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their function as negative regulators of other NLRP proteins (e.g.
NLRRP3) by NACHT-NACHT interactions.
The present study revealed further evidence for the complex
interconnections of NLR proteins, however, based on interactions
not involving the NACHT-domains. We found NOD2 to interact
with NLRP1, NLRP3, and NLRP12. These results suggest an
intimate connection or a complex crosstalk between NOD2 and
NLRP signaling.
Recently, data on a prospective connection between NOD2 and
NLRP signaling pathways began to emerge. It was shown that
MDP-induced IL-1b release requires both NOD2 as well as
NLRP3 [27]. The group assigned essential, non-redundant roles
for NOD2 and NLRP3 in processing pro-IL-1b, and proposed
NOD2 to be part of the NLRP3 inflammasome on the basis of a
CARD-independent interaction. However, the group referred to
the requirement of further studies to determine whether NOD2
and NRLP3 are indeed part of the same complex. The data
presented in our study reveal a direct interaction of NLRP3 and
NOD2, in a CARD-dependent manner. We therefore anticipate
that both proteins are in fact part of the inflammasome. In
particular as the interaction surface for NOD2 does not comprise
the PYD of NLRP3, leaving the possibility that NLRP3 can still
recruit ASC and activate caspase-1 when complexed with NOD2.
Notably, during implementation of our experiments another
report on the NOD2/NLRP connection was released [29]. This
group reported co-immunoprecipitation of epitope-tagged NOD2
and NLRP1 in transiently transfected HEK293T cells upon MDP
challenge. Furthermore, size exclusion chromatography revealed
the formation of a complex consisting of NOD2 and NLRP1 that
activates caspase-1 in response to MDP. Accordingly, unique and
non-redundant functions of NOD2 and NLRP1 in formation of an
MDP-responsive inflammasome that is responsible for processing
and secretion of IL-1b were postulated.
Interestingly, the consequence of NOD2 mutations on the
production of interleukins and the progression of Crohn’s disease
are controversial (reviewed in [57]). Accordingly, the effect of
Crohn’s disease-associated NOD2 mutations on IL-1b production
differs between human and mouse macrophages. The basis for this
discrepancy is not known. Consequently, Hsu et al suggest that the
actual consequence of NOD2 mutations may rely on the NOD2/
NLRP1 interaction [29].
In full agreement with the study of Hsu et al we found a direct
interaction of NOD2 and NLRP1. Moreover our studies provide
additional mechanistic insights, since we demonstrated that
NOD2 selectively interacted with NLRP3 and NLRP12, but not
with NLRP2, NLRP7, NLRP10, or NRLP11.
Finally, we found that a short isoform of NOD2, called NOD2-
S, interacts with NLRPs, while further truncations of NOD2 did
not. NOD2-S was recently described as an alternatively spliced
form of NOD2 that is truncated within the second CARD domain
[23]. NOD2-S was demonstrated to bind full length NOD2 and
was found to inhibit NOD2 signaling in a dominant-negative
fashion. Hence, NOD2-S represents a down-regulatory loop by
which NOD2 is able to modulate its own activation. Whether
interaction of NOD2-S with NLRP1, NLRP3 and NLRP12 also
represents a down-regulatory loop for NLRP signaling remains to
be investigated.
In summary, our study revealed additional layers of complexity
for NLR interactions which underscores the importance of further
studies to identify novel downstream effectors of NLR signaling on
a genome-wide level. In this respect, the identification of a
connection between NOD2 and the NLRP subfamily adds




Coding sequences for effector domains of 11 distinct NLR
proteins (NOD1, NOD2, NLRP1, NLRP2, NLRP3, etc.), three
adaptor molecules (RIPK2, ASC, PYDC1), as well as five caspases
Figure 5. NOD2 directly interacts with NLRP1, NLRP3, and NLRP12. Left panel, Yeast two-hybrid analysis of NOD2 CARDs (residues 1–267)
showed interaction with NLRP1,-3 and -12, but not with other NLRP proteins (NLRP2, -7, -10, or -11; column 1). Lam c was used as a negative control
(column 2). Interestingly, NOD2 mutant E69K maintained the binding to NLRP1, -3, and -12 (column 3), whereas NOD2 D70K (column 4) as well as the
NOD2 triple mutant (3xmut, column 5) did not. An unrelated mutation not located within the prospective interaction interface had no effect (column 6).
Rightpanel,PhysicalinteractionofNOD2andNLRP3inhumancells.Westernanalysisoflysates(IN)andimmunoprecipitatedcomplexes(IP)fromHEK293T
cells,transientlytransfectedwithexpressionplasmidencodinghumanHA-NOD2andFLAG-NLRP3.NLRP3wasimmunoprecipitatedfromcelllysatesusing
a FLAG-epitope specific antibody. Proteins were detected using anti-HA and anti-FLAG antibodies, respectively. As negative control, proteins were
immunoprecipitated with FLAG-epitope specific antibody from lysates of HEK293T cells transiently transfected with HA-NOD2, but not FLAG-NLRP3.
doi:10.1371/journal.pone.0004931.g005
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binding (pGBKT7, Clontech) as well as the GAL4 transcription
activation domain (pGADT7), respectively. Since some proteins
(NOD2, NLRP1, ASC) feature more than one CARD or pyrin
domain a total number of 26 distinct effector domain fusions was
generated. A complete compilation of constructs is found in
Table 2. All constructs were sequenced by MWG Biotech
(Germany) and subsequently subjected to yeast two-hybrid
analysis.
Mammalian expression vector for HA-NOD2 was a kind gift
from G. Nunez. The expression vector for NLRP3 was obtained
from J. Tschopp.
Yeast two-hybrid analysis
We applied the MATCHMAKER GAL4 Two-Hybrid System
3 (CLONTECH). Two-Hybrid experiments were performed
essentially as described in the manufactures instructions. Briefly,
the Saccharomyces cerevisiae reporter strain AH109 was transformed
simultaneously with certain combinations of pGBKT7-based and
pGADT7-based fusion constructs using a small scale lithium
acetate/single-stranded carrier DNA/polyethylene glycol (LiAc/
ss-DNA/PEG) transformation protocol [58]. Transformed yeast
cells were resuspended in sterile water and spotted onto SD/-
Leu/-Trp dropout medium to assess transformation efficiency and
onto SD/-Ade/-His/-Leu/-Trp selection medium to test for
potential interactions. Plates were incubated for 4 days at 30uC.
To rule out any artificial interactions all fusion constructs were
pre-tested for autoactivating properties and association with either
the GAL4-DNA binding or GAL4-activation domain, respective-
ly. Co-transformation of pGBKT7-p53 and pGADT7-T served as
positive interaction control, while the combination of pGBKT7-
Lamc and pGADT7-T represented the negative control.
Combinations of fusion constructs positive for activation of
reporter genes were confirmed by repeated small scale transfor-
mation and growth on appropriate minimal synthetic dropout
media.
Figure 6. NOD2 interaction with distinct NLRP members. Upper panel,A‘ ‘ +’’ indicates an interaction, ‘‘2’’ symbolizes no interaction (n.d.: not
done). A short isoform of NOD2 (NOD2-S, residues 1–180), maintains the interaction with NLRP1, -3, and -12. Furthermore, a linker region within
NLRP1 (residues 92–341) proved sufficient for interaction with NOD2. Lower panel, Schematic illustration of particular NOD2/NLRP1 constructs and
their respective interactions. FIIND: Function to find domain.
doi:10.1371/journal.pone.0004931.g006
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PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e4931The strength of potential interactions was assessed by spotting
transformants on SD/-His/-Leu/-Trp supplemented with increas-
ing amounts 3-aminotriazole.
Screening
Following initial trails, yeast transformations were conducted in
an ‘‘each against all’’ approach, i.e. every GAL4 DNA-binding
domain fusion construct was tested for association with any GAL4
transcription activation domain fusion construct, resulting in an
overall number of 676 (26626) independent transformations. The
well established association between the CARDs of apoptosis
protease activating factor-1 (APAF-1) and caspase-9 was consid-
ered as a paradigm for a CARD-CARD-mediated binding and
served as prove of principle.
Since, all constructs were tested as both GAL4 DNA-BD as well
as GAL4 AD fusions the 25 recorded associations actually
corresponded to 12 unique effector domain interactions (see
Table). All combinations of fusion constructs scoring positive for
an interaction were validated by repeating transformations and
selection on dropout medium.
GST pull down assay
GST fusion proteins were expressed from pGEX-4T1 in E. coli
BL21 star (Invitrogen) and affinity-purified using glutathione-
Sepharose 4B beads (Amersham Pharmacia Biotech). Prey
proteins were generated in vitro using the reticulocyte lysate TNT
T7 Quick Coupled Transcription/Translation System (Promega)
in the presence of [
35S]methionine as described by the
manufacturer. Purified GST fusion proteins (0.5 mg) immobilized
on 15 ml of GSH-Sepharose beads were incubated with 5 mlo f
translation reaction containing
35S-labeled proteins in 500 ml
binding buffer (PBS+0.1% NP-40 supplemented with 5 mg/ml
Aprotinin; 5 mg/ml Leupeptin;1 mM Pefabloc SC) for 2 h at 4uC
under constant agitation. Proteins on beads were washed four
times in 1 ml of binding buffer. Bound proteins were eluted by
boiling for 5 min in SDS sample buffer, subjected to SDS-PAGE,
and analyzed by fluorography.
In vivo co-immunoprecipitation
For immunoprecipitation, HEK293T cells (cultivated at 37uC
with 5% CO2 in Dulbecco’s modified Eagle’s medium (Gibco-
BRL) supplemented with 10% heat-inactivated fetal calf serum
(Gibco-BRL) and penicillin-streptomycin (100 IU/ml and
100 mg/ml, respectively; Gibco-BRL)) were transiently transfect-
ed, using FuGene6 (Roche) according to the manufacturer’s
conditions, with the indicated plasmids (1 mg plasmid per 6-cm
dish) and incubated for 48 h. Cells were lysed in NP-40 buffer
(150 mM NaCl, 1% NP-40, 50 mM Tris-HCl, pH 7.5) containing
phosphatase inhibitors (20 mM b-glycerophosphate, 5 mM NaF,
100 mM Na3VO4, and Complete protease inhibitor cocktail
[Roche]). Lysates were cleared for 20 min at 14,0006ga t4 uC.
Immunoprecipitation was subsequently carried out for 4 h at
4uC by adding anti-FLAG beads (M2 gel; Sigma-Aldrich) to the
cell extracts. The beads were precipitated by centrifugation steps
and washed five times in NP-40 buffer before sodium dodecyl
sulfate loading buffer was added. Typically, about 10 to 20 times
more precipitate than input was loaded into the gel. Proteins were
separated by Laemmli sodium dodecyl sulfatepolyacrylamide gel
electrophoresis and transferred by semidry Western transfer to a
nitrocellulose membrane (Bio-Rad). Proteins were detected by
incubation of the membrane subsequently with primary and
secondary antibodies and by a final incubation with SuperSignal
West Pico maximum sensitivity substrate (Pierce). Primary
antibodies were mouse anti-FLAG M2 (1:1000) (F3165; Sigma-
Aldrich), rabbit anti-HA (1:1,000) (sc-805; Santa Cruz Biotech-
nology). Secondary antibodies were horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG (1:4,000) (170-6616; Bio-
Rad), HRP-conjugated goat anti-rabbit IgG (1:4,000) (170-6515;
Bio-Rad).
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